Ezose Sciences Announces Appointment of Chief Operating Officer
Complete the form below to unlock access to ALL audio articles.
Ezose Sciences Inc. announced that Scott A. Siegel, Ph.D., Vice President, Business Development, has been named Chief Operating Officer, a new position at the company.
Dr. Siegel will assume broad responsibility for operations at Ezose, which focuses on glycomics research to identify biomarkers for use in drug development and disease management, and to characterize biotherapeutic glycoforms. He will also continue to lead Business Development. In his new role he will continue to report to Kiyoshi Nagata, Ph.D., Chairman and Chief Executive Officer of Ezose.
"Scott has made Ezose a partner of choice for healthcare companies and academic institutions that seek to realize the promise of glycomics in their R&D programs," said Dr. Nagata. "At the same time, his talents and energies have already supported various operational activities at Ezose. We look forward to the still broader contributions he will make in his new position.
"The naming of a chief operating officer, together with the other appointments we are announcing today, demonstrates our commitment to helping our partners establish glycomics as a basic tool in their biomedical research."
Dr. Siegel brings to his role more than 25 years of experience in the biotechnology and pharmaceutical industries. Before joining Ezose in 2009 he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company. Earlier, he held various positions in New Business Development and Worldwide Strategic Marketing at Johnson & Johnson. He has served in R&D capacities at Phytera, Inc., Centocor, Inc., and Becton Dickinson and Co., and as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade(R) (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders.
Dr. Siegel earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.
In other recent appointments, Ezose named:
-- Diane McCarthy, Ph.D., Director, Scientific Affairs. Dr. McCarthy was previously a longtime consultant to Ezose. She has held various leadership positions in the biotechnology industry, particularly in the field of proteomics and biomarkers. She earned a doctorate in Biochemistry at the University of Texas at Austin.
-- Ezra Jennings, Ph.D., Senior Scientist. Dr. Jennings has developed bioinformatics tools as a consultant to the Whitehead Institute for Biomedical Research and as a senior scientist at a biotech company focusing on diagnostics. He has a doctorate in Biology from the Massachusetts Institute of Technology.
-- Joshua Alfaro, Ph.D., Scientist. Dr. Alfaro has conducted various research projects in academic and government laboratories, including development of glycopeptide-enrichment methods. His doctorate in Organic Chemistry was earned at Washington State University
